Multicenter performance evaluation of the Atellica IM HBcT2 immunoassay for risk or symptom-driven hepatitis B core antibody testing

Background: Hepatitis B virus (HBV) causes major liver disease and despite widespread vaccination, HBV infection, often asymptomatic, remains a global health issue. Serological detection of HBV biomarkers, including total antibodies (IgM and IgG) to hepatitis B core antigen (HBc) is recommended as a...

Descripció completa

Dades bibliogràfiques

Autors principals:	Matthew F.W. Gee, Maria Pagano, Marie-Elena Grosett, Brendan Healy, Sara Kastrup Shah, Eugene R. Schiff
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2026-06-01
Col·lecció:	Journal of Clinical Virology Plus
Matèries:	Hepatitis B virus (HBV) Hepatitis B core antibody Serological testing Clinical performance Seroconversion Positive percent agreement (PPA)
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2667038026000049
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!